StockData

CervoMed vs Talphera

CRVO and TLPH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRVO and TLPH compare

Talphera is the larger company, worth 1.8 times as much as CervoMed ($41.6M against $22.7M).

CervoMed grew revenue faster over the last twelve months (−95.7% versus −96.3% for Talphera).

CervoMed keeps more of each dollar of sales as profit, with a net margin of −9161% compared with −1507600% at Talphera.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRVOTLPH
Size and price
Market cap$22.7M$41.6M
Share price$1.50$0.801
Change, 1 year−80.5%−35.9%
Change, 5 years−94.9%−93.8%
Beta (5Y)3.411.28
Employees1512
StockData Score
Total score55
Valuation score1 (better)0
Growth score00
Performance score00
Health score45 (better)
Dividend score00
Valuation
P/S68.5× (better)41566×
P/B1.0× (better)2.9×
Growth
Revenue growth (TTM)−95.7% (better)−96.3%
Revenue growth, 5Y average–−65.1%
Profitability
Operating margin−9407% (better)−1474700%
Net margin−9161% (better)−1507600%
Return on equity−108% (better)−143%
Financial health
Debt / equity0.000.00
Current ratio–4.29
Altman Z-score−5.50 (better)−24.17
Piotroski F-score15 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions11.6%54.4%
Held by insiders36.9%46.8%
Insider net buying, 12 months$3.0M (better)$304K
Short interest, % of float12.7%4.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.